2 years ago

Carcinotech Secures £4.2 Million to Accelerate Cancer Drug Development

  • Carcinotech, a Scottish startup producing 3D printed micro-tumours, secured £4.2 million in funding led by Eos Advisory

  • The round also included participation from the Investment Fund for Scotland, Maven Capital Partners, Scottish Enterprise, Old College Capital, Investing Women Angels, and existing investors TRICAPITAL, SIS Ventures, Gabriel Investment Syndicate, and Alba Equity

  • The company plans to use the funds to expand its operations and research and development efforts.

      • ProblemHealthcare

      "Current cancer drug testing is slow and inefficient, relying on animal models that don't always accurately reflect human biology. This delays the development of effective treatments and limits the availability of personalized medicine."

      Solution

      "Carcinotech's 3D printed micro-tumours, created using patient cells, offer a more accurate and ethical alternative to animal models. These micro-tumours accurately simulate the tumour microenvironment, enabling faster and more effective drug screening, leading to faster development of personalized cancer treatments."

      Covered on